The success of the first treatment plays a crucial role in the prognosis of lymphoma. Before treatment, we must fully understand the patient’s organism status, pathological type, clinical stage and other factors, accurately assess the prognosis, and formulate a planned and reasonable comprehensive treatment plan to achieve the best treatment effect. Although the proportion of radiation therapy in the treatment of lymphoma has decreased in recent years, it is still one of the important treatment means for patients with limited stage, and even for patients with progressive stage, radiation therapy for local residual lesions still has important clinical significance. Radiation therapy for pediatric patients must be administered with great caution to avoid disruption of growth and development and long-term complications. Lymphomas originating in the gastrointestinal tract that develop or are likely to develop obstruction or perforation often require surgical treatment first. In recent years, monoclonal antibodies against specific antigens, high-dose chemotherapy supported by autologous stem cells, and the application of new antitumor drugs have led to new improvements in the efficacy of lymphoma, treatment has become more individualized, and patients’ quality of life has received more attention and assurance. Hodgkin’s lymphoma has become a curable disease, and the overall long-term disease-free survival rate of non-Hodgkin’s lymphoma is over 50%. I. Treatment of Hodgkin’s lymphoma Depending on the stage of the disease, patients with Hodgkin’s lymphoma will have different treatment strategies. The principle of treatment for localized Hodgkin’s lymphoma is the combination of chemoradiotherapy, and reasonable comprehensive treatment can achieve a 5-year disease-free survival rate of 85%-95%. Systemic chemotherapy is the mainstay of treatment for patients in the progressive stage, and 5-year disease-free survival can reach 30%-85%. The principle of second-line chemotherapy regimen selection should be based on the type of relapse and previous treatment. High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation is an alternative treatment option for relapsed patients. Treatment of non-Hodgkin’s lymphoma Small lymphocytic lymphoma: Stage I or II patients can be treated with local radiotherapy or observation. Treatment should be considered in the presence of the following conditions: clinical symptoms, mass threatening organ function, hematocrit, large mass, continued progression of disease, change in pathological type, or patient request for treatment. Stage III or IV patients with autoimmune hematocrit in addition to the above should be considered for treatment if accompanied by